INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10541687	
Filing Date		2005-11-21	
First Named Inventor	DEADWYLER		
Art Unit		1615	
Examiner Name	KIM,	KIM, Jennifer M.	
Attorney Docket Number		C21-074US Nat	

	1	INGVAR M et al., Enhancement by an ampakine of memory encoding in humans. Exp. Neurol. 1997 Aug; 146 (2):553-9. Abstract only.			
	2	GOFF DC et al., The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry 2001 Sep; 158(9):1357-77. Abstract only.			
	3	MARCENO S et al., Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr Res. 2002 Oct 1; 57(2-3):221-6. Abstract only.			
	4	MACKOWIAK M et al., An AMPA receptor potentiator modulates hippocampal expression of BDMF: an in vivo study. Neuropharmacology 2002; 43:1-10.			
	5 QUIRK JC et al., LY404187: A Novel Positive Allosteric Modulator of AMPA Receptors. CNS Drug Reviews 2002; 8 (3):255-282.				
If you wis	h to a	dd additional non-patent literature document citation information please click the Add button			
		EXAMINER SIGNATURE			
Examiner Signature Date Considered					
		uitial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a conformance and not considered. Include copy of this form with next communication to applicant.			

See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.